Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
ATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq:ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Ireland. Reimbursement was granted by the Health Service Executive Corporate Pharmaceutical Unit and National Centre for Pharmacoeconomics in Ireland in line with its label in Europe.
Related news for (ALIM)
- ani pharmaceuticals, inc. completes acquisition of alimera sciences
- ani pharmaceuticals initiates closing of acquisition of alimera sciences
- ani pharmaceuticals provides update on closing of acquisition of alimera sciences
- alimera sciences takes legal action against ani pharmaceuticals to enforce merger agreement
- The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®